Feature | May 19, 2014

Pacemaker, Defibrillator Patients Adhering to Remote Monitoring Saw More Than Double Survival Rate

Data presented during at Heart Rhythm 2014 is industry’s largest study of remote management of pacemaker patients

May 19, 2014 — St. Jude Medical announced that data presented during a late-breaking clinical trial session at the 2014 annual scientific sessions of the Heart Rhythm Society (HRS) found an association between adherence to remote monitoring with the Merlin remote monitoring system and a reduction in patient mortality. Results from more than 260,000 patients implanted with either pacemakers or defibrillators demonstrated that patients with high adherence to remote monitoring had more than twice (2.4x) the probability of survival than that of patients without remote monitoring.

The prospective, observational study of U.S. patients also found that the greater the adherence to remote monitoring, the better the patient fared. Patients with high adherence to remote monitoring — measured as weekly transmission of patient data from the [email protected] System to the Merlin.net patient care network at least 75 percent of the time — overall had a 58 percent reduced likelihood of mortality than patients not using remote monitoring and a 35 percent reduced likelihood of mortality than patients with low remote monitoring. Though there was geographic variability, socioeconomic factors were not associated with remote monitoring use.

“This study is the first of its kind to find increased survival when remote monitoring is utilized in pacemaker patients,” said Suneet Mittal, M.D., director of EP at the Valley Hospital Health System of N.Y. and N.J. “Furthermore, our data suggest that, irrespective of whether a patient has a pacemaker or defibrillator, higher use of remote monitoring is associated with better survival. Although these associations require further investigation, these important observations should have significant implications for individual patient care and best-practice guidelines.”

All St. Jude Medical U.S. Food and Drug Administration (FDA) approved implantable cardiac devices capable of radiofrequency (RF) remote monitoring were included in the study, which had a cohort of 262,564. This is the largest study to date of remote monitoring pacemaker patients, and one of the largest for remote monitoring overall.

“Patients with implanted cardiac devices are typically required to visit doctors’ offices several times per year to have their device performance checked, which for many can be impractical. This new research demonstrates that the Merlin patient care system not only adds convenience for physicians and patients, it helps patients to live longer,” said Mark D. Carlson, M.D., chief medical officer for St. Jude Medical.

For more information: www.sjm.com

Related Content

heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
mitral valve surgery outcomes, twisting of the heart, echocardiography, NICSMR, JACC Basic to Translational Science
News | Heart Valve Technology| July 20, 2016
A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart...
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign, Trialign system, tricuspid regurgitation. SCOUT U.S. study, phase 1 enrollment
News | Heart Valve Technology| July 19, 2016
Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the...
Dictum Health, telehealth study, IDM100 tablet, neonate cardiology, in-home monitoring
Technology | Telecardiology| July 19, 2016
Dictum Health Inc. announced the launch of a post-U.S. Food and Drug Administration (FDA)-approval study of its end-to-...
sudden cardiac arrest, out-of-hospital, comatose patients, University of Arizona study, wake up
News | Sudden Cardiac Arrest| July 13, 2016
Physicians may be drawing conclusions too soon about survival outcomes of patients who suffered a cardiac arrest...
radial access, inserting stents, JACC Cardiovascular Interventions study
News | Radial Access| July 13, 2016
A new study in JACC: Cardiovascular Interventions supports access through the wrist, or radial access, as the default...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing| July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies| July 12, 2016 | Heidi Olsen, Pharm.D
With the recent introduction of several novel oral...
University of Guelph study, heart failure risk, gender, aging
News | Heart Failure| July 08, 2016
University of Guelph researchers have uncovered a possible clue as to why women have lower rates of heart failure than...
Overlay Init